JP2022512911A5 - - Google Patents

Info

Publication number
JP2022512911A5
JP2022512911A5 JP2021524019A JP2021524019A JP2022512911A5 JP 2022512911 A5 JP2022512911 A5 JP 2022512911A5 JP 2021524019 A JP2021524019 A JP 2021524019A JP 2021524019 A JP2021524019 A JP 2021524019A JP 2022512911 A5 JP2022512911 A5 JP 2022512911A5
Authority
JP
Japan
Prior art keywords
inventions
patient
compound
administration
death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021524019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512911A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059632 external-priority patent/WO2020095274A1/en
Publication of JP2022512911A publication Critical patent/JP2022512911A/ja
Publication of JP2022512911A5 publication Critical patent/JP2022512911A5/ja
Priority to JP2024031803A priority Critical patent/JP2024081645A/ja
Priority to JP2025169038A priority patent/JP2026021335A/ja
Pending legal-status Critical Current

Links

JP2021524019A 2018-11-09 2019-11-08 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法 Pending JP2022512911A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024031803A JP2024081645A (ja) 2018-11-09 2024-03-04 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法
JP2025169038A JP2026021335A (ja) 2018-11-09 2025-10-07 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862758323P 2018-11-09 2018-11-09
US62/758,323 2018-11-09
US201962874459P 2019-07-15 2019-07-15
US62/874,459 2019-07-15
PCT/IB2019/059632 WO2020095274A1 (en) 2018-11-09 2019-11-08 Method for reducing the risk of a cardiovascular event with conjugated antisense compounds targeting apo(a)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024031803A Division JP2024081645A (ja) 2018-11-09 2024-03-04 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法

Publications (2)

Publication Number Publication Date
JP2022512911A JP2022512911A (ja) 2022-02-07
JP2022512911A5 true JP2022512911A5 (enExample) 2022-11-11

Family

ID=68582078

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021524019A Pending JP2022512911A (ja) 2018-11-09 2019-11-08 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法
JP2024031803A Pending JP2024081645A (ja) 2018-11-09 2024-03-04 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法
JP2025169038A Pending JP2026021335A (ja) 2018-11-09 2025-10-07 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024031803A Pending JP2024081645A (ja) 2018-11-09 2024-03-04 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法
JP2025169038A Pending JP2026021335A (ja) 2018-11-09 2025-10-07 ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法

Country Status (9)

Country Link
US (2) US20210395737A1 (enExample)
EP (1) EP3877523A1 (enExample)
JP (3) JP2022512911A (enExample)
KR (2) KR20210091703A (enExample)
CN (1) CN113286885A (enExample)
AU (3) AU2019377275A1 (enExample)
CA (1) CA3111382A1 (enExample)
IL (1) IL281147A (enExample)
WO (1) WO2020095274A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
WO2003014397A1 (en) 2001-08-09 2003-02-20 Biomedlab Corporation Probe for detection of enteric virus detection kit and method for enteric virus with the same
RU2624028C2 (ru) 2012-05-24 2017-06-30 Ионис Фармасьютикалз, Инк. Способы и композиции для модулирования экспрессии аполипопротеина (а)
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
WO2015168589A2 (en) * 2014-05-01 2015-11-05 Isis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
AU2016349625B2 (en) 2015-11-06 2022-07-07 Ionis Pharmaceuticals, Inc. Modulating apolipoprotein (a) expression
LT4119569T (lt) * 2015-11-06 2024-09-25 Ionis Pharmaceuticals, Inc. Konjuguoti priešprasmiai junginiai, skirti panaudoti terapijoje

Similar Documents

Publication Publication Date Title
JP2022062151A5 (enExample)
Prys-Roberts et al. Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma
ES2241305T3 (es) Combinaciones contra la diabetes que contienen gliburide, troglitazona (y una biguanida).
JP2023549115A5 (enExample)
EP3448416B1 (en) Semaglutide in cardiovascular conditions
KR20110026422A (ko) 영구적 심방 세동의 예방을 위한 드로네다론
Bosch Medical treatment of portal hypertension
CA2979448A1 (en) Treat of type 2 diabetes mellitus patients
KR20120138229A (ko) 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료
KR20120089623A (ko) 정맥내 투여용 이부프로펜을 이용한 환자의 치료
ES2250749T3 (es) Uso de una composicion combinada que comprende propionil l-carnitina y otros farmacos para el tratamiento de la disfuncion erectil.
Krott et al. Adjunctive hyperbaric oxygenation in macular edema of vascular origin
KR20140032380A (ko) 확장성 울혈성 심부전 치료제
TW201210586A (en) Methods of using diacerein as an adjunctive therapy for diabetes
US5906974A (en) Hemoglobin therapy in hemodialysis
AU2014356392A1 (en) Sprayable aqueous composition comprising glyceryl trinitrate
CN102149376B (zh) 症状性心力衰竭的长期治疗
Kambam et al. Histamine2 receptor blocker in the treatment of protamine related anaphylactoid reactions: two case reports
RU2022129009A (ru) Способ снижения риска развития сердечно-сосудистого события с помощью конъюгированных антисмысловых соединений, нацеливающихся на apo(a)
CA2889584C (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
Iida et al. Treatment of dialysis-induced hypotension with L-threo-3, 4-dihydroxyphenylserine
Van Uum et al. Successful haemodialysis in sotalol-induced torsade de pointes in a patient with progressive renal failure.
RU2021116145A (ru) Способ снижения риска развития сердечно-сосудистого события с помощью конъюгированных антисмысловых соединений, нацеливающихся на apo(a)
Hamid et al. Hypotension following valve replacement surgery in carcinoid heart disease
AU2002220960A1 (en) Regeneration of blood vessels